Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib - Revolution Medicines (NASDAQ:RVMD)

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib - Revolution Medicines (NASDAQ:RVMD)

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy First Breakthrough Therapy Designation for an investigational drug specifically targeting KRAS G12D mutation in NSCLC Revolution Medicines' third RAS(ON) inhibitor to receive…

FDA Grants Breakthrough Status to Zoldonrasib in Lung Cancer

FDA granted breakthrough therapy designation to zoldonrasib for previously treated KRAS G12D-mutated non-small cell lung cancer.